Publication:
Identificación de epitopes de los dominios V11V2 de la proteína de envoltura del VIH-1, reconocidos por anticuerpos IgA neutralizantes aislados de saliva de parótida de pacientes VIH-1

Simple item page
dc.contributor.authorUrcuqui-Inchima, Silvio
dc.contributor.researchgroupInmunovirología/GIMAP
dc.date.accessioned2023-12-18T11:20:11Z
dc.date.available2023-12-18T11:20:11Z
dc.date.issued2004
dc.description.abstractEl VIH-1 es el agente responsable del síndrome de inmunodeficiencia adquirida (SIDA). Alrededor de 40 millones de personas están infectados con el VIH-1 y cada año se infectan aproximadamente unos 5 millones de personas, de las cuales, casi la mitad corresponde a mujeres. En Colombia, se estima que la prevalencia varía entre el 0.4 y el 1.2%, lo que equivale aproximadamente a 190.000 personas infectadas con el VIH-1. La mucosa representa una de las principales vías de infección por el VIH-1 después de un contacto sexual. Esta constituye un tejido linfoide especializado, particularmente independiente del sistema inmunitario sistémico. Por ejemplo, las IgG representan un componente mayoritario del sistémico, mientras que la IgA secretoria (S-lgA) constituye la primera barrera inmunitaria, cuya principal función es impedir la colonización de la mucosa por parte de los agentes patógenos, e impedir la penetración del organismo. Las S-lgA actúan por exclusión inmune, por transcitos de complejos inmunes localizados en posición su-epitelial y por eliminación directa de virus que penetran en las células epiteliales.spa
dc.description.tableofcontents1. Título y código del proyecto 2. Número del contrato que lo respalda 3. Nombre de la entidad ejecutora, del investigador principal y del grupo de investigación 4. Sinopsis divulgativa 5. Sinopsis técnica Español Inglés. 6. Resumen técnico. 7. Cuadro de resultados de generación de conocimiento. 8. Cuadro de otros resultados. 9. Descripción del impacto actual o potencial de los resultados . 10. Anexos.spa
dc.format.extent23 p.
dc.format.mimetypeapplication/pdf
dc.identifier.urihttps://repositorio.minciencias.gov.co/handle/20.500.14143/50056
dc.language.isospa
dc.publisherUniversidad de Antioquia
dc.publisherColciencias
dc.publisher.placeMedellín
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.creativecommonsAtribución 4.0 Internacional (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.lembSida -- Prevención
dc.subject.lembSida -- Tratamiento
dc.subject.lembProyectos de investigación
dc.subject.lembVacunas
dc.subject.proposalVIH-1spa
dc.titleIdentificación de epitopes de los dominios V11V2 de la proteína de envoltura del VIH-1, reconocidos por anticuerpos IgA neutralizantes aislados de saliva de parótida de pacientes VIH-1spa
dc.typeInforme de investigación
dc.type.coarhttp://purl.org/coar/resource_type/c_18ws
dc.type.contentText
dc.type.driverinfo:eu-repo/semantics/report
dc.type.redcolhttp://purl.org/redcol/resource_type/INF
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dcterms.audienceEstudiantes, Profesores, Comunidad científica colombiana, etc.spa
dcterms.referencesWendler.l, Bienzle U and Hunsmann G: Neutralizing antibodies and the course of HIV-induced disease. AIDS Res Hum Retroviruses 1987;3 :157-163.
dcterms.referencesFreed EO and Martin MA: Evidence for a functional interaction between the Vl/V2 and e4 domains of human immunodeficiency virus type 1 envelope glycoprotein gp 120. J Viral 1994;68:2503-2512
dcterms.referencesSullivan N, Thali M, Furman e , Ho DD and Sodroski J: Effect of amino acid changes in the Vl/V2 region ofthe human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation , and recognition by a neutralizing antibody. J Viral 1993;67:3674-3679.
dcterms.referencesVeIJa e, King D, Zheng NN, Fickenscher H, Breuer J and Daniels RS: Alterations in the VI/V2 domain ofHIV-2eBL24 glycoprotein 105 corre late with an extended cell tropismo AIDS Res Hum Retroviruses 1999;15:1399-1402
dcterms.referencesWyatt R, Moore J, Accola M, Desjardin E, Robinson J and Sodroski J: Involvement of the VIN2 variable loop structure in the exposure ofhuman immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Viral 1995;69:5723-5733.
dcterms.referencesKoito A, Harrowe G, Levy JA and eheng-Mayer e: Functional role ofthe VI/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp 120 in infection of primary macrophages and soluble eD4 neutralization. J Viral 1994;68:2253-2259.
dcterms.referencesFung MS, Sun eR, Gordon WL, et al. : Identification and characterization of a neutralization site within the second variable region ofhuman immunodeficiency virus type 1 gp120.J Viral 1992;66:848-856.
dcterms.referencesGorny MK, Moore lP, Conley AJ, et al.: Human anti -V2 monoclonal antibody that neutralizes primary but not laboratory isolates ofhuman immunodeficiency virus type 1. J Viral 1994;68 :8312-8320 .
dcterms.referencesHo DD, Fung MS, Cao YZ, et al.: Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc Natl Acad Sci U S A 1991 ;88 :8949-8952.
dcterms.referencesWarrier SV, Pinter A, Honnen WJ, Girard M, Muclmlore E and Tilley SA: A novel, glycan-dependent epitope in the V2 doma in ofhuman immunodeficiency virus type I gpl20 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. J Viral 1994;68:4636-464
dcterms.referencesMcKeating lA, Shotton C, Cordell J, et al.: Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains ofhuman immunodeficiency virus type 1 gp 120. J Viral 1993;67:4932-4944.
dcterms.referencesShotton C, ArnoJd C, Sattentau Q, Sodroski J and McKeating JA: Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region ofthe human immunodeficiency virus type 1 envelope glycoprotein. J Viral 1995;69 :222-230.
dcterms.referencesPinter A, Honnen WJ, Kayman SC, Trochev O and Wu Z: Potent neutraJization of primary HIV-I isolates by antibodies directed against epitopes present in the Vl/V2 domain ofHIV-l gp120. Vaccine 1998;16:1803-1811.
dcterms.referencesCao J, Sullivan N, Desjardin E, et al.: Replication and neutralization ofhuman immunodeficiency virus type 1 lacking the VI and V2 variable Joops ofthe gp 120 envelope glycoprotein. J Viral 1997;71 :9808-9812.
dcterms.referencesWu Z, Kayman SC, Honnen W, et al.: Characterization ofneutralization epitopes in the V2 region ofhuman immunodeficiency virus type 1 gp 120: role of glycosy lation in the correct folding ofthe VI/V2 domain. J Viro 1 1995;69:2271-2278
dcterms.referencesAlexander S and Elder JH: Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens. Science 1984;226:1328-1330
dcterms.referencesHansen JE, Clausen H, Nielsen C, et al.: lnhibition ofhuman immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HlV envelope glycoprotein gp 120 may be a target forvirus neutralization. J Virol 1990;64:2833-2840.
dcterms.referencesLosman B, Bolmstedt A, Schonning K, et al.: Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by Nlinked oligosaccharides in the VI region. AIDS Res Hum Retroviruses 2001; 17: 1067-1076.
dcterms.referencesWolk T and Schreiber M: N-Glycans in the gp120 VI/V2 domain ofthe HIV-l strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization. Med Microbiollmmunol (Berl) 2006.
dcterms.referencesLy A and Stamatatos L: V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction ofthis protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J ViroI2000;74:6769-6776 .
dcterms.referencesQuinones-Kochs MI, Buonocore L and Rose JK: Role ofN-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J ViroI2002;76:4199-421 l.
dcterms.referencesKrachmarov CP, Honnen WJ, Kayman SC, Gorny MK, Zolla-Pazner S and Pinter A: Factors determining the breadth and potency of neutralization by V3-specific human
dcterms.referencesmonoclonal antibodies derived from subjects infected with cIad e A or c1ade B strains of human immunodeficiency virus type l. J ViroI2006 ;80:7127-7 135.
dcterms.referencesMoja P, Tranchat e, Tchou 1, et al. : Neutralization ofhuman immunodeficiency virus type 1 (HIV -1) mediated by parotid IgA of HIV -1-infected patients. J lnfect Dis 2000;181: 1607-1613.
dcterms.referencesVincent N, Malvoisin E, Pozzetto B, Lucht F and Genin e: Detection of IgA inhibiting the interaction between gp 120 and soluble eD4 receptor in serum and saliva of HIV -1- infected patients. Aids 2004;18:37-43 .
dcterms.referencesKayman se, Wu Z, Revesz K, ehen H, Kopelman R and Pinter A: Presentation of native epitopes in the V JIY2 and V3 regions of human immunodeficiency virus type 1 gp 120 by fusion glycoproteins containing isolated gp 120 domains. J Viro 1 1994;68 :400-41 O.
dcterms.referencesSouthern lA, Young DF, Heaney F, Baumgartner WK and Randall RE: Identification of an epitope on the P and V proteins of simian virus 5 that distinguishes between two iso lates with different biological characteristics. J Gen Viro 1 1991 ;72 ( Pt 7): 1551-1557.
dcterms.referencesLindner P, Bauer K, Krebber A, et al.: Specific detection ofhis-tagged proteins with recombinant anti-His tag scFv-phosphatase or scFv-phage fusions. Biotechniques 1997;22: 140-149
dcterms.referencesThompson JD, Gibson TJ, Plewniak F, leanmougin F and Higgins DG: The eLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997;25:4876-4882.
dcterms.referencesFelgner PL and Ringold GM: eationic liposome-mediated transfection. Nature 1989;337:387-388.
dcterms.referencesFelgner PL, Holm M and ehan H: eationic liposome mediated transfection. Proc West Pharmacol Soc 1989;32: 115-12l.
dcterms.referencesGritz L and Davies J: Plasmid-encoded hygromycin B resistance: the sequence of hygromycin B phosphotransferase gene and its expression in Escherichia coli and Saccharomyces cerevisiae. Gene 1983;25:179-188 .
dcterms.referencesKoch M, Frazier J, Sodroski J and Wyatt R: Characterization of antibody responses to purified HIV-l gp120 glycoproteins fused with the molecular adjuvant C3d. Virology 2005;340:277-284.
dcterms.referencesStamatatos L, Wiskerchen M and Cheng-Mayer C: Effect ofmajor deletions in the VI and V2 loops of a macrophage-tropic HIV type 1 iso late on viral envelope structure, cell entry, and replication. AIDS Res Hum Retroviruses 1998; 14: 1129-1139
dcterms.referencesWei X, Decker 1M, Wang S, et al. : Antibody neutralization and escape by HIV-l. Nature 2003 ;422:307-312
dcterms.referencesCartry O, Moja P, Quesnel A, Pozzetto B, Lucht FR and Genin C: Quantification of IgA and IgG and specificities of antibodies to viral proteins in parotid saliva at different stages ofHIV-l infection. Clin Exp ImmunoI1997 ;109:47-53.
dcterms.referencesWestervelt P, Trowbridge DB, Epstein LG, et al. : Macrophage tropism determinants ofhuman immunodeficiency virus type 1 in vivo. J Viral 1992;66:2577-2582.
dcterms.referencesMoore JP, Sattentau QJ, Yoshiyama H, et al.: Probing the structure ofthe V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp 120 with a panel of eight monoclonal antibodies: human immune response to the VI and V2 domains. J Viral 1993;67:6136-6151.
dcterms.referencesPincus SH, Messer KG, Nara PL, Blatlner WA, Colclough G and Reitz M: Temporal analysis ofthe antibody response to HIV envelope protein in HIV-infected laboratory workers. J Clin lnvest 1994;93 :2505-2513
dcterms.referencesGram GJ, Hemming A, Bolmstedt A, et al.: Identification of an N-Iinked glycan in the VI-loop ofHIV-l gpI20 influencing neutralization by anti-V3 antibodies and soluble CD4. Arch Viro 1 1994;139:253-261.
dcterms.referencesMcKeating JA, Thali M, Furman C, et al. : Amino acid residues ofthe human immunodeficiency virus type 1 gp 120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. Virology 1992;190:134-142.
dcterms.referencesRencher SD and Hurwitz JL: Effect of natural HIV-l envelope Vl-V2 sequence diversity on the binding ofV3-specific and non-V3-specific antibodies. J Acquir lmmune Deflc Syndr Hum RetroviroII997 ;I6:69 -73 .
dcterms.referencesMorikita T, Maeda Y, Fujii S, Matsushita S, Obaru K and Takatsuki K: The Vl/V2 region ofhuman immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropismo AIDS Res Hum Retroviruses 1997;13 :1291-1299.
dcterms.referencesFox DG, Balfe P, Palmer CP, May JC, Arnold C and McKeating JA: Length polymorphism within the second variable region ofthe human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site. J Viro1I997;71 :759- 765.
dcterms.referencesBinley JM, Wyatt R, Desjardins E, et al.: Analysis ofthe interaction ofantibodies with a conserved enzymaticaJly deglycosylated core ofthe HIV type 1 envelope glycoprotein 120. AIDS Res Hum Retroviruses 1998;14 :191 -198.
dcterms.referencesStamatatos L and Cheng-Mayer C: An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J ViroI1998;72:7840-7845 .
dcterms.referencesVijh-Warrier S, Pinter A, Honnen WJ and TilIey SA: Synergistic neutralization of human immunodeficiency virus type 1 by a chimpanzee monoclonal antibody against the V2 domain of gp 120 in com bination with monoclonal antibodies against the V3 loop and the eD4-binding site. J Viro 1 1996;70:4466-4473.
dcterms.referencesVijh-Warrier S, Murphy E, Yokoyama 1 and TilIey SA: eharacterization ofthe variable regions of a chimpanzee monoclonal antibody with potent neutralizing activity against HIV-l. Mol ImmunoI1995;32 :1081-1092.
dcterms.referencesKennedy Re, Henkel RD, Pauletti D, et al.: Antiserum to a synthetic peptide recognizes the HTLV-lII envelope glycoprotein. Science 1986;231:1556-1559. 50. McKeating JA, Shotton e , Jeffs S, et al.: Immunogenicity offulI length and truncated forms ofthe human immunodeficiency virus type 1 envelope glycoprotein. Immunol Lea 1996;51 :101-105 .
dcterms.referenceseheng-Mayer e , Brown A, Harouse J, Luciw PA and Mayer Al: Selection for neutralization resistance ofthe simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify Nlinked glycosylation. J Viro11999 ;73 :5294-5300.
dcterms.referencesElder JH, McGee JS and Alexander S: earbohydrate side chains ofRauscher leukemia virus envelope glycoproteins are not required to elicit a neutralizing antibody response. J ViroI1986;57:340-342.
dspace.entity.typePublication
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2
oaire.awardnumber11150416402
oaire.awardtitleIdentificación de epitopes de los dominios V1N2 de la proteína de envoltura del VIH-1, reconocidos por anticuerpos IgA neutral izantes aislados de saliva de parótida de pacientes VIH-1
oaire.funderidentifier.colciencias269-2004
oaire.fundernameDepartamento Administrativo de Ciencia, Tecnología e Innovación [CO] Colciencias
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
11150416402.pdf
Size:
62.05 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
15.18 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Informes Finales de Proyectos de Investigación